Shanghai MicroPort MedBot SEHK 2252 Narrows EPS Loss Challenging Persistent Bearish Profitability Narratives

Shanghai MicroPort MedBot (Group) (SEHK:2252) reported FY 2025 first half revenue of C¥175.7 million with a basic EPS loss of C¥0.11, setting the tone for another period where top line expansion and bottom line pressure sit side by side for investors tracking the story at a share price of C¥25.74. The company has seen revenue build from C¥99.2 million in 1H 2024 to C¥158.0 million in 2H 2024 and then to C¥175.7 million in 1H 2025. Over the same period, basic EPS moved from a loss of C¥0.29 to a loss of C¥0.37 and then to a loss of C¥0.11, so the latest release keeps the focus squarely on how quickly margins can move toward breakeven.

See our full analysis for Shanghai MicroPort MedBot (Group).

With the headline numbers on the table, the next step is to set these results against the widely followed growth and risk narratives to see which parts of the story hold up and where expectations may need a reset.

Curious how numbers become stories that shape markets? Explore Community Narratives

Revenue at C¥551.1 million on a trailing basis

• On a trailing 12 month basis, total revenue is C¥551.1 million, compared with C¥333.7 million at the prior trailing data point and C¥257.2 million at the one before that, so the reported 30.8% annual revenue growth rate is backed by steadily larger sales footprints in the data.
• Bulls often lean on this kind of revenue progression, and here the trailing revenue climb sits alongside forecasts of about 95.41% yearly earnings growth and an expectation of profitability within three years. Yet the same dataset shows trailing net income still at a loss of C¥249.7 million, which means:
  • The growth story is supported by larger reported revenue over each trailing period, while the earnings side still reflects sizeable losses that need to narrow before those bullish expectations line up with the current income statement.
  • For anyone leaning toward the bullish view, the mix of higher revenue and ongoing losses makes the pace of cost control and operating leverage a key factor to watch, rather than revenue alone.

Losses and EPS still firmly in the red

• Net income, excluding extra items, was a loss of C¥113.4 million in 1H 2025, after losses of C¥365.2 million in 2H 2024 and C¥277.2 million in 1H 2024, with trailing 12 month net loss at C¥249.7 million and trailing EPS at a loss of C¥0.24, so the company remains clearly unprofitable even as half year EPS loss narrowed to C¥0.11 in the latest period.
• Bears highlight that the company is still unprofitable and that losses over the past five years have grown by about 1.3% per year, and this is echoed by the trailing figures which show hundreds of millions of CNY in losses. Yet these same bears have to weigh that against analysts forecasting strong earnings growth of roughly 95.41% per year, which creates a tension:
  • The historical pattern of losses and the current trailing loss of C¥249.7 million back up concerns about the business model not yet covering its cost base.
  • At the same time, the expectation of a shift to profitability within three years sits in sharp contrast to the current loss profile, so readers need to decide how much weight to place on the historical track record versus those forward looking earnings estimates.

Premium P/S multiple versus DCF fair value gap

• At a share price of C¥25.74 and a P/S of 42.5x, the stock trades at more than double the peer average P/S of 19.8x and well above the Hong Kong medical equipment industry average of 4.7x. Yet a DCF fair value of C¥35.14 in the supplied data sits about 26.7% above the current price, and there is also a single allowed analyst price target of C¥31.78 that stands between the market price and that DCF figure.
• What is interesting for a bullish style view is that the DCF fair value of C¥35.14 and the C¥31.78 analyst price target both sit above the current C¥25.74 share price, while bears can point to the 42.5x P/S multiple being far higher than peers and the industry, so valuation pulls in two different directions:
  • The premium P/S multiple supports the bearish concern that investors are already paying a high price for each C¥1 of trailing sales compared with the sector and peer group.
  • The gap between C¥25.74 and both the C¥31.78 analyst target and the C¥35.14 DCF fair value, together with revenue at C¥551.1 million on a trailing basis, is the kind of setup bulls might use to argue that the market is not fully reflecting the growth profile that analysts and the DCF assumptions are working with.

To see how other investors are weighing that growth, loss profile, and valuation trade off over time, check out the broader community discussion for this stock and where expectations are clustering right now. 📊 Read the what the Community is saying about Shanghai MicroPort MedBot (Group).

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Shanghai MicroPort MedBot (Group)'s growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Given the mix of optimism and caution in this story, it is worth checking the numbers yourself and moving quickly to form your own view. Then weigh both sides with the 2 key rewards and 1 important warning sign

Explore Alternatives

Shanghai MicroPort MedBot (Group) still carries sizeable losses and a premium 42.5x P/S multiple, so profitability and valuation risk remain front of mind.

If that kind of risk profile feels uncomfortable right now, you may wish to shift your focus toward companies screened for stronger downside protection by checking out 279 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com